Trial Information

Official Title: Open-label, Single-arm, Flexible Dosing, Phase III Trial, With Oral Tapentadol PR in Subjects With Chronic Malignant Tumor-related Pain Who Have Completed the Maintenance Period of the KF5503/15 Trial.

Summary

The purpose of this trial is the characterization of the long term safety profile and long-term dose requirements of tapentadol ER in patients with malignant tumor-related pain.

Phase: Phase 3

Sponsor: Grünenthal GmbH

Overall Contacts:

René Allard
+49 241 569 3223
Clinical-Trials@grunenthal.com